EMA401: An old antagonist of the AT2R for a new indication in neuropathic pain

Journal of Pain Research

Volumn 10, Issue , 2017, Pages 439-443

  Hesselink, Jan M Keppel ^a   Schatman, Michael E ^b  

^a Institute of Neuropathic Pain   (Netherlands)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiotensin II type 2 receptor; Antagonist; Development; Drug repositioning; EMA401; Neuropathic pain; Novel

Indexed keywords

ANALGESIC AGENT; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; EMA 400; EMA 401; PD 126055; PLACEBO; UNCLASSIFIED DRUG;

ARTICLE; DRUG EFFICACY; DRUG STRUCTURE; HUMAN; NEUROPATHIC PAIN; NONHUMAN; TREATMENT INDICATION;

EID: 85013853157     PISSN: None     EISSN: 11787090     Source Type: Journal    
DOI: 10.2147/JPR.S128520     Document Type: Article

References (25)

1. McKinley MJ, Albiston AL, Allen AM, et al. The brain renin-angiotensin system: locationandphysiological roles. Int JBiochemCell Biol. 2003;35(6): 901–918.
2. Bohlender J, Imboden H. Angiotensinergic neurotransmission in the peripheral autonomic nervous system. Front Biosci. 2012;17:2419–2432.
3. Smith MT, Wyse BD, Edwards SR. Small molecule angiotensin II type 2 receptor (AT2R) antagonists as novel analgesics for neuropathic pain: comparative pharmacokinetics, radioligand binding and efficacy in rats. Pain Med. 2013;14(5):692–705.
4. McCarthy T. Spinifex Pharmaceuticals EMA401: A Novel Treatment of Neuropathic Pain. Australasian Life Science Investment Summit. November 2, 2012. Melbourne, VIC, Australia.
5. Nishimura H. Renin-angiotensin system in vertebrates: phylogenetic view of structure and function. Anat Sci Int. Epub 2016 Oct 7.
6. Hunyady L, Catt KJ. Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. Mol Endocrinol. 2006;20(5):953–970.
7. Tsutsumi K, Saavedra JM. Characterization and development of angiotensin II receptor subtypes (AT1 and AT2) in rat brain. Am J Physiol. 1991;261(1 pt 2):R209–R216.
8. Allen AM, Moeller I, Jenkins TA, et al. Angiotensin receptors in the nervous system. Brain Res Bull. 1998;47(1):17–28.
9. Pelegrini-da-Silva A, Martins AR, Prado WA. A new role for the renin-angiotensin system in the rat periaqueductal gray matter: angiotensin receptor-mediated modulation of nociception. Neuroscience. 2005; 132(2):453–463.
10. Porrello ER, Delbridge LMD, Thomas WG. The angiotensin II type 2 (AT2) receptor: an enigmatic seven transmembrane receptor. Front Biosci. 2009;14:958–972.
11. Wan Y, Wallinder C, Plouffe B, et al. Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist. J Med Chem. 2004;47(24):5995–6008.
12. McCarthy CA, Vinh A, Callaway JK, Widdop RE. Angiotensin AT2 receptor stimulation causes neuroprotection in a conscious rat model of stroke. Stroke. 2009;40(4):1482–1489.
13. Alterman M. Development of selective non-peptide angiotensin II type 2 receptor agonists. J Renin Angiotensin Aldosterone Syst. 2010;11(1): 57–66.
14. Anand U, Facer P, Yiangou Y, et al. Angiotensin II type 2 receptor (AT2 R) localization and antagonist-mediated inhibition of capsaicin responses and neurite outgrowth in human and rat sensory neurons. Eur J Pain. 2013;17(7):1012–1026.
15. Blankley CJ, Hodges JC, Klutchko S, inventors; Warner-Lambert Company. Patent: substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties US 5246943 A. 1992 May 19.
16. Smith MT, Wyse BD, inventors; The University Of Queensland. Patent: method of treatment or prophylaxis. WO 2006066361 A1. 2004 Dec 24.
17. England KG. PCT Written Opinion of the International Searching Authority. April 26, 2006.
18. Papp M, Li X, Zhuang J, Wang R, Uhal BD. Angiotensin receptor subtype AT(1) mediates alveolar epithelial cell apoptosis in response to ANG II. Am J Physiol Lung Cell Mol Physiol. 2002;282(4): L713–L718.
19. Mantlo NB, Kim D, Ondeyka D, et al. Potent imidazo[4,5-b]- pyridine angiotensin II antagonists which exhibit balanced affinity to the AT1 and AT2 receptor subtypes. Bioorg Med Chem Lett. 1994;4:17–22.
20. Smith MT, Wyse BD, Edwards SR. Small molecule angiotensin II type 2 receptor (AT2R) antagonists as novel analgesics for neuropathic pain: comparative pharmacokinetics, radioligand binding, and efficacy in rats. Pain Med. 2013;14(5):692–705.
21. Rice AS, Dworkin RH, McCarthy TD, et al. EMA401-003 study group. EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial. Lancet. 2014;383(9929):1637–1647.
22. McCarthy T. Development of EMA401 as an orally-administered, highly-selective angiotensin II type 2 receptor antagonist for the treatment of neuropathic pain. J Peripher Nerv Syst. 2014;19(Suppl 2): S13–S14.
23. Smith MT, Anand P, Rice AS. Selective small molecule angiotensin II type 2 receptor antagonists for neuropathic pain: preclinical and clinical studies. Pain. 2016;157(Suppl 1):S33–S41.
24. Novartis. Reimagining Medicine. Available from: https://www.novartis. com/sites/www.novartis.com/files/2016-01-novartis-jpm-presentation.pdf. Accessed January 27, 2016.
25. Novartis. Q4 and Full Year 2015 Results. Available from: https://www. novartis.com/sites/www.novartis.com/files/q4-2015-ir-presentation.pdf. Accessed January 27, 2016.